Log in

NASDAQ:SMMTSUMMIT THERAPEU/S Stock Price, Forecast & News

$4.04
+0.03 (+0.75 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.94
Now: $4.04
$4.05
50-Day Range
$2.57
MA: $3.58
$4.40
52-Week Range
$1.13
Now: $4.04
$5.49
Volume16,510 shs
Average Volume147,529 shs
Market Capitalization$129.68 million
P/E RatioN/A
Dividend YieldN/A
Beta0.59
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.
Read More
SUMMIT THERAPEU/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.01 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SMMT
CUSIPN/A
Phone44-12-3544-3939

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$56.50 million
Cash Flow$1.13 per share
Book Value$4.08 per share

Profitability

Net Income$9.99 million
Net Margins-2,107.69%

Miscellaneous

Employees61
Market Cap$129.68 million
Next Earnings Date6/10/2020 (Estimated)
OptionableOptionable

Receive SMMT News and Ratings via Email

Sign-up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.

SUMMIT THERAPEU/S (NASDAQ:SMMT) Frequently Asked Questions

How has SUMMIT THERAPEU/S's stock been impacted by COVID-19 (Coronavirus)?

SUMMIT THERAPEU/S's stock was trading at $1.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SMMT stock has increased by 113.8% and is now trading at $4.04. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of SUMMIT THERAPEU/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SUMMIT THERAPEU/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for SUMMIT THERAPEU/S.

When is SUMMIT THERAPEU/S's next earnings date?

SUMMIT THERAPEU/S is scheduled to release its next quarterly earnings announcement on Wednesday, June 10th 2020. View our earnings forecast for SUMMIT THERAPEU/S.

How were SUMMIT THERAPEU/S's earnings last quarter?

SUMMIT THERAPEU/S (NASDAQ:SMMT) announced its quarterly earnings results on Wednesday, March, 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.13. The company had revenue of $0.66 million for the quarter, compared to analyst estimates of $4.44 million. SUMMIT THERAPEU/S had a negative return on equity of 59.95% and a negative net margin of 2,107.69%. View SUMMIT THERAPEU/S's earnings history.

What price target have analysts set for SMMT?

1 brokers have issued twelve-month price targets for SUMMIT THERAPEU/S's stock. Their forecasts range from $4.00 to $4.00. On average, they expect SUMMIT THERAPEU/S's stock price to reach $4.00 in the next year. This suggests that the stock has a possible downside of 1.0%. View analysts' price targets for SUMMIT THERAPEU/S.

Has SUMMIT THERAPEU/S been receiving favorable news coverage?

Media stories about SMMT stock have been trending negative this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. SUMMIT THERAPEU/S earned a daily sentiment score of -2.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutSUMMIT THERAPEU/S.

Who are some of SUMMIT THERAPEU/S's key competitors?

What other stocks do shareholders of SUMMIT THERAPEU/S own?

Who are SUMMIT THERAPEU/S's key executives?

SUMMIT THERAPEU/S's management team includes the following people:
  • Mr. Glyn O. Edwards, CEO & Exec. Director (Age 63)
  • Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 53)
  • Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 69)
  • Ms. Melissa Strange FCCA, VP of Fin. & Company Sec. (Age 39)
  • Ms. Michelle Avery, Director of Investor Relations

When did SUMMIT THERAPEU/S IPO?

(SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.

What is SUMMIT THERAPEU/S's stock symbol?

SUMMIT THERAPEU/S trades on the NASDAQ under the ticker symbol "SMMT."

Who are SUMMIT THERAPEU/S's major shareholders?

SUMMIT THERAPEU/S's stock is owned by many different institutional and retail investors. Top institutional investors include Morgan Stanley (0.61%), Acadian Asset Management LLC (0.28%) and Inscription Capital LLC (0.05%).

Which major investors are selling SUMMIT THERAPEU/S stock?

SMMT stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, and Morgan Stanley.

Which major investors are buying SUMMIT THERAPEU/S stock?

SMMT stock was bought by a variety of institutional investors in the last quarter, including Inscription Capital LLC.

How do I buy shares of SUMMIT THERAPEU/S?

Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SUMMIT THERAPEU/S's stock price today?

One share of SMMT stock can currently be purchased for approximately $4.04.

How big of a company is SUMMIT THERAPEU/S?

SUMMIT THERAPEU/S has a market capitalization of $129.68 million and generates $56.50 million in revenue each year. The company earns $9.99 million in net income (profit) each year or $0.84 on an earnings per share basis. SUMMIT THERAPEU/S employs 61 workers across the globe.

What is SUMMIT THERAPEU/S's official website?

The official website for SUMMIT THERAPEU/S is www.summitplc.com.

How can I contact SUMMIT THERAPEU/S?

SUMMIT THERAPEU/S's mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 44-12-3544-3939 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.